{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:09:05Z","timestamp":1785150545430,"version":"3.55.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"Supplement_D","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Orion Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute heart failure (AHF) continues to be a substantial cause of illness and death, with in-hospital and 3-month mortality rates of 5% and 10%, respectively, and 6-month re-admission rates in excess of 50% in a range of clinical trials and registry studies; the European Society of Cardiology (ESC) Heart Failure Long-Term Registry recorded a 1-year death or rehospitalization rate of 36%. As regards the short-term treatment of AHF patients, evidence was collected in the ESC Heart Failure Long-Term Registry that intravenous (i.v.) treatments are administered heterogeneously in the critical phase, with limited reference to guideline recommendations. Moreover, recent decades have been characterized by a prolonged lack of successful innovation in this field, with a plethora of clinical trials generating neutral or inconclusive findings on long-term mortality effects from a multiplicity of short-term interventions in AHF. One of the few exceptions has been the calcium sensitizer and inodilator levosimendan, introduced 20 years ago for the treatment of acutely decompensated chronic heart failure. In the present review, we will focus on the utility of this agent in the wider context of i.v. inotropic and inodilating therapies for AHF and related pathologies.<\/jats:p>","DOI":"10.1093\/eurheartj\/suaa090","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:35:46Z","timestamp":1594992946000},"page":"D3-D11","source":"Crossref","is-referenced-by-count":10,"title":["Short-term treatments for acute cardiac care: inotropes and inodilators"],"prefix":"10.1093","volume":"22","author":[{"given":"Fabio","family":"Guarracino","sequence":"first","affiliation":[{"name":"Dipartimento di Anestesia e Terapie Intensive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endre","family":"Zima","sequence":"additional","affiliation":[{"name":"Cardiac Intensive Care, Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Pollesello","sequence":"additional","affiliation":[{"name":"Critical Care Proprietary Products, CO, Orion Pharma, PO Box 65, FIN-02101 Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Masip","sequence":"additional","affiliation":[{"name":"Intensive Care Department, Consorci Sanitari Integral, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"2020071623495491000_suaa090-B1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2015.10.240","article-title":"Calcium sensitizers: what have we learned over the last 25 years?","volume":"203","author":"Pollesello","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","article-title":"Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper","volume":"222","author":"Farmakis","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.15420\/cfr.2019.11.2","article-title":"Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice","volume":"5","author":"Bistola","year":"2019","journal-title":"Card Fail Rev"},{"key":"2020071623495491000_suaa090-B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2019.09.005","article-title":"A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus","volume":"297","author":"Farmakis","year":"2019","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B6","doi-asserted-by":"crossref","first-page":"G19","DOI":"10.1093\/eurheartj\/suw045","article-title":"The bumpy road to drug development for acute heart failure","volume":"18","author":"Hamo","year":"2016","journal-title":"Eur Heart J Suppl"},{"key":"2020071623495491000_suaa090-B7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/jcm8111834","article-title":"Short-term therapies for treatment of acute and advanced heart failure: why so few drugs available in clinical use, why even fewer in the pipeline?","volume":"8","author":"Pollesello","year":"2019","journal-title":"J Clin Med"},{"key":"2020071623495491000_suaa090-B8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"2020071623495491000_suaa090-B9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"key":"2020071623495491000_suaa090-B10","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2020.03","article-title":"Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use","author":"Papp","year":"2020","journal-title":"Card Fail Rev"},{"key":"2020071623495491000_suaa090-B11","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","article-title":"Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure","volume":"296","author":"Gheorghiade","year":"2006","journal-title":"JAMA"},{"key":"2020071623495491000_suaa090-B12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2020071623495491000_suaa090-B13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00134-010-2113-0","article-title":"Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF)","volume":"37","author":"Follath","year":"2011","journal-title":"Intensive Care Med"},{"key":"2020071623495491000_suaa090-B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijcard.2016.04.064","article-title":"Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: sub-analysis of the Finnish patients","volume":"215","author":"Kivikko","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijcard.2016.05.009","article-title":"The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion","volume":"218","author":"Nieminen","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2020071623495491000_suaa090-B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2016.02.014","article-title":"Levosimendan meta-analyses: is there a pattern in the effect on mortality?","volume":"209","author":"Pollesello","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B18","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/bja\/aeu446","article-title":"A Bayesian network meta-analysis on the effect of inodilatory agents on mortality","volume":"114","author":"Greco","year":"2015","journal-title":"Br J Anaesth"},{"key":"2020071623495491000_suaa090-B19","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.2174\/1389201011208062522","article-title":"Alteration of the beta-adrenergic signaling pathway in human heart failure","volume":"13","author":"Hamdani","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"2020071623495491000_suaa090-B20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cardfail.2014.07.008","article-title":"Acute heart failure with and without concomitant acute coronary syndromes: patient characteristics, management, and survival","volume":"20","author":"Tarvasm\u00e4ki","year":"2014","journal-title":"J Card Fail"},{"key":"2020071623495491000_suaa090-B21","first-page":"CD009669","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome","volume":"1","author":"Schumann","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071623495491000_suaa090-B22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00134-015-4041-5","article-title":"Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance","volume":"42","author":"Mebazaa","year":"2016","journal-title":"Intensive Care Med"},{"key":"2020071623495491000_suaa090-B23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40256-017-0237-0","article-title":"Effects of levosimendan on patients with heart failure complicating acute coronary syndrome: a meta-analysis of randomized controlled trials","volume":"17","author":"Shang","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"2020071623495491000_suaa090-B24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"key":"2020071623495491000_suaa090-B25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2020071623495491000_suaa090-B26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071623495491000_suaa090-B27","doi-asserted-by":"crossref","first-page":"e71659","DOI":"10.1371\/journal.pone.0071659","article-title":"The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis","volume":"8","author":"Pirracchio","year":"2013","journal-title":"PLoS One"},{"key":"2020071623495491000_suaa090-B28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","article-title":"Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods","volume":"37","author":"Mebazaa","year":"2011","journal-title":"Intensive Care Med"},{"key":"2020071623495491000_suaa090-B29","first-page":"2732","article-title":"Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock","volume":"35","author":"Russ","year":"2007","journal-title":"Crit Care Med"},{"key":"2020071623495491000_suaa090-B30","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","article-title":"Levosimendan for hemodynamic support after cardiac surgery","volume":"376","author":"Landoni","year":"2017","journal-title":"N Engl J Med"},{"key":"2020071623495491000_suaa090-B31","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"2020071623495491000_suaa090-B32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aew151","article-title":"Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery","volume":"117","author":"Distelmaier","year":"2016","journal-title":"Br J Anaesth"},{"key":"2020071623495491000_suaa090-B33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MAT.0b013e3182a4b32e","article-title":"Levosimendan may improve weaning outcomes in venoarterial ECMO patients","volume":"59","author":"Affronti","year":"2013","journal-title":"ASAIO J"},{"key":"2020071623495491000_suaa090-B34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13613-019-0503-1","article-title":"Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit","volume":"9","author":"Vally","year":"2019","journal-title":"Ann Intensive Care"},{"key":"2020071623495491000_suaa090-B35","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1053\/j.jvca.2018.04.019","article-title":"Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery\u2014A retrospective before-and-after study","volume":"32","author":"Jacky","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2020071623495491000_suaa090-B36","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","article-title":"International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"2020071623495491000_suaa090-B37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jchf.2018.10.015","article-title":"Does levosimendan have room in Takotsubo syndrome?","volume":"7","author":"Tavazzi","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2020071623495491000_suaa090-B38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijcard.2016.08.281","article-title":"If channel blocker ivabradine vs. \u03b2-blockers for sinus tachycardia in patients with takotsubo syndrome","volume":"223","author":"Madias","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020071623495491000_suaa090-B39","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2020071623495491000_suaa090-B40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/aas.13486","article-title":"Levosimendan or milrinone for right ventricular inotropic treatment?\u2014A secondary analysis of a randomized trial","volume":"64","author":"Fredholm","year":"2020","journal-title":"Acta Anaesthesiol Scand"},{"key":"2020071623495491000_suaa090-B41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1067\/mcp.2000.110972","article-title":"Myocardial efficiency during levosimendan infusion in congestive heart failure","volume":"68","author":"Ukkonen","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"2020071623495491000_suaa090-B42","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"2020071623495491000_suaa090-B43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lfs.2017.07.001","article-title":"Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis","volume":"184","author":"Qiu","year":"2017","journal-title":"Life Sci"},{"key":"2020071623495491000_suaa090-B44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00380-008-1077-2","article-title":"Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure","volume":"24","author":"Yilmaz","year":"2009","journal-title":"Heart Vessels"},{"key":"2020071623495491000_suaa090-B45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1742-1241.2007.01510.x","article-title":"Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure","volume":"62","author":"Duygu","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2020071623495491000_suaa090-B46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/j.jvca.2016.01.015","article-title":"Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction","volume":"30","author":"Mishra","year":"2016","journal-title":"J Cardiothor Vasc Anesth"},{"key":"2020071623495491000_suaa090-B47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1074248417696818","article-title":"Dose-response head-to-head comparison of inodilators dobutamine, milrinone, and levosimendan in chronic experimental pulmonary hypertension","volume":"22","author":"Tavares-Silva","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2020071623495491000_suaa090-B48","doi-asserted-by":"crossref","first-page":"204589401870905","DOI":"10.1177\/2045894018790905","article-title":"Levosimendan in pulmonary hypertension and right heart failure","volume":"8","author":"Hansen","year":"2018","journal-title":"Pulm Circ"},{"key":"2020071623495491000_suaa090-B49","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","article-title":"Levosimendan for the prevention of acute organ dysfunction in sepsis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"2020071623495491000_suaa090-B50","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","article-title":"Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial","volume":"45","author":"Antcliffe","year":"2019","journal-title":"Intensive Care Med"},{"key":"2020071623495491000_suaa090-B51","doi-asserted-by":"crossref","first-page":"e019338","DOI":"10.1136\/bmjopen-2017-019338","article-title":"Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials","volume":"8","author":"Chang","year":"2018","journal-title":"BMJ Open"},{"key":"2020071623495491000_suaa090-B52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13054-018-2144-4","article-title":"Refractory septic shock: our pragmatic approach","volume":"22","author":"Nandhabalan","year":"2018","journal-title":"Crit Care"},{"key":"2020071623495491000_suaa090-B53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13054-016-1439-6","article-title":"Left ventricular function: time-varying elastance and left ventricular aortic coupling","volume":"20","author":"Walley","year":"2016","journal-title":"Crit Care"},{"key":"2020071623495491000_suaa090-B54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/cc12522","article-title":"Ventriculo-arterial decoupling in acutely altered hemodynamic states","volume":"17","author":"Guarracino","year":"2013","journal-title":"Crit Care"},{"key":"2020071623495491000_suaa090-B55","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1399-6576.2007.01428.x","article-title":"Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy","volume":"51","author":"Guarracino","year":"2007","journal-title":"Acta Anaesthesiol Scand"},{"key":"2020071623495491000_suaa090-B56","doi-asserted-by":"crossref","first-page":"H488","DOI":"10.1152\/ajpheart.01116.2010","article-title":"Levosimendan restores the positive force-frequency relation in heart failure","volume":"301","author":"Masutani","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020071623495491000_suaa090-B57","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1067\/mhj.2001.119610","article-title":"Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact","volume":"142","author":"Yamani","year":"2001","journal-title":"Am Heart J"},{"key":"2020071623495491000_suaa090-B58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","article-title":"Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials","volume":"38","author":"Tacon","year":"2012","journal-title":"Intensive Care Med"},{"key":"2020071623495491000_suaa090-B59","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00392-015-0852-1","article-title":"A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list","volume":"104","author":"H\u00fcbner","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"2020071623495491000_suaa090-B60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/aor.12150","article-title":"Preconditioning with levosimendan before implantation of left ventricular assist devices","volume":"38","author":"Theiss","year":"2014","journal-title":"Artif Organs"},{"key":"2020071623495491000_suaa090-B61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/MAT.0b013e318239f401","article-title":"Preoperative treatment with levosimendan in candidates for mechanical circulatory support","volume":"58","author":"Sponga","year":"2012","journal-title":"ASAIO J"},{"key":"2020071623495491000_suaa090-B62","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/sux001","article-title":"The inodilator levosimendan as a treatment for acute heart failure in various settings","volume":"19","author":"Gustafsson","year":"2017","journal-title":"Eur Heart J Suppl"},{"key":"2020071623495491000_suaa090-B63","doi-asserted-by":"crossref","first-page":"I2","DOI":"10.1093\/eurheartj\/suy039","article-title":"Use of levosimendan in acute heart failure","volume":"20","author":"Harjola","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"2020071623495491000_suaa090-B64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.15420\/cfr.2019.01.R1","article-title":"Hemodynamic balance in acute and advanced heart failure: an expert perspective on the role of levosimendan","volume":"5","author":"Agostoni","year":"2019","journal-title":"Card Fail Rev"},{"key":"2020071623495491000_suaa090-B65","doi-asserted-by":"crossref","first-page":"I11","DOI":"10.1093\/eurheartj\/suy040","article-title":"Tsch\u00f6pe Repetitive levosimendan treatment in the management of advanced heart failure","volume":"20","author":"Oliva","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"2020071623495491000_suaa090-B66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FJC.0000000000000533","article-title":"Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications","volume":"71","author":"Altenberger","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"2020071623495491000_suaa090-B67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10557-018-6838-2","article-title":"Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application","volume":"32","author":"Bouchez","year":"2018","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_D\/D3\/33211963\/suaa090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_D\/D3\/33211963\/suaa090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:36:00Z","timestamp":1594992960000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/22\/Supplement_D\/D3\/5836983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":67,"journal-issue":{"issue":"Supplement_D","published-online":{"date-parts":[[2020,5,15]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suaa090","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]}}}